Issue Date: April 5, 2010
Companies Ink siRNA Deals
More companies have plans to develop small-interfering-RNA-based drugs. Dicerna Pharmaceuticals and Ipsen will work together to improve the delivery of siRNA. The goal is to make novel conjugates of Dicerna's dicer-substrate siRNA molecules and Ipsen's peptide-targeting vectors to develop therapeutics for oncology and endocrinology. In a separate deal, Silence Therapeutics and Dainippon Sumitomo Pharma have expanded an siRNA delivery pact they initiated in August. The new deal adds . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society